Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
Devalingam Mahalingam, Grey Wilkinson, Kevin H. Eng, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 1, pp. 71-81
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Therapy with oncolytic viruses: progress and challenges
Sophia Z. Shalhout, David M. Miller, Kevin S. Emerick, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 160-177
Closed Access | Times Cited: 271
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Jamal Majidpoor, Keywan Mortezaee
Clinical Immunology (2021) Vol. 226, pp. 108707-108707
Closed Access | Times Cited: 172
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 162
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
Tao Shi, Xueru Song, Yue Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 140
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi, Do‐Youn Oh, Antoine Hollebecque, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e002068-e002068
Open Access | Times Cited: 131
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2429-2429
Open Access | Times Cited: 75
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Yangfu Jiang, Hongying Zhang, Jiao Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 72
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
Conner Hartupee, Bolni Marius Nagalo, Chiswili Chabu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 25
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
Benjamin Musher, Eric K. Rowinsky, Brandon G. Smaglo, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 4, pp. 488-500
Closed Access | Times Cited: 19
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Ritu Singh, Eileen M. O’Reilly
Drugs (2020) Vol. 80, Iss. 7, pp. 647-669
Open Access | Times Cited: 132
Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients
Yongping Zhou, Wei Qian, Junsheng Fan, et al.
Clinica Chimica Acta (2018) Vol. 479, pp. 181-189
Closed Access | Times Cited: 130
Pancreatic cancer in 2021: What you need to know to win
Valeria Tonini, Manuel Zanni
World Journal of Gastroenterology (2021) Vol. 27, Iss. 35, pp. 5851-5889
Open Access | Times Cited: 99
Pancreatic Cancer and Immunotherapy: A Clinical Overview
Florentine E. F. Timmer, Bart Geboers, Sanne Nieuwenhuizen, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4138-4138
Open Access | Times Cited: 95
Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease
Hong Yuen Wong, Quanhu Sheng, Amanda B. Hesterberg, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 68
Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
Yaqi Zhao, Zheming Liu, Lan Li, et al.
Frontiers in Microbiology (2021) Vol. 12
Open Access | Times Cited: 67
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Lingyue Liu, Xing Huang, Fukang Shi, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 58
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bruno Bockorny, Joseph E. Grossman, Manuel Hidalgo
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4606-4617
Closed Access | Times Cited: 56
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy
Weiyue Ban, Jianhuan Guan, Hanwei Huang, et al.
Nano Research (2022) Vol. 15, Iss. 5, pp. 4137-4153
Open Access | Times Cited: 55
Oncolytic viruses: challenges and considerations in an evolving clinical landscape
Ulrich M. Lauer, Julia Beil
Future Oncology (2022) Vol. 18, Iss. 24, pp. 2713-2732
Open Access | Times Cited: 47
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
Chae‐Ok Yun, JinWoo Hong, A‐Rum Yoon
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects
Lingjuan Chen, Mengsi Zuo, Qin Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
Application of oncolytic virus in tumor therapy
Zhijian Huang, Hongen Guo, Lin Lin, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 25
Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective
Palaniyandi Muthukutty, So Young Yoo
Viruses (2023) Vol. 15, Iss. 8, pp. 1645-1645
Open Access | Times Cited: 25
Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
Hui Dong, Mengli Li, Chen Yang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top